Clinical Impact
The Decision Sciences model moves fibrosis management from 'how much scar is there?' toward 'is the scar still actively driving the disease, and can we still turn it around?' — enabling earlier, more targeted, and more effective interventions while improving prognostic accuracy for patients and clinicians alike.
The Unmet Need
The Clinical Imperative
Hepatic fibrosis affects an estimated 1.5 billion people worldwide. The majority of cirrhosis cases — and virtually all hepatocellular carcinoma arising from fibrosis — are preventable if intervention occurs before the irreversibility threshold. The clinical problem is not a lack of treatments. It is a lack of tools to identify which patients are approaching that threshold, and when.
Intervention Strategy
Stage-Dependent Therapeutic Windows
Therapeutic leverage is not uniform across fibrosis stages — it peaks at F2 and falls sharply thereafter. Understanding this changes how clinical trials should be designed, how patients should be stratified, and which molecular targets are actionable at each stage.
Optimal Intervention Window
F2 is the point of maximum therapeutic leverage. The AGE burden is below the autonomous signaling threshold, sRAGE production from the intact hepatocyte population is sufficient to neutralize circulating AGEs, and the fibrogenic loop is still injury-dependent. Injury removal yields ~68% resolution at F2. RAGE-targeted therapy at this stage amplifies that response further — the biology is still working in the patient's favor. This is the window to act.
Primary target
Injury removal + RAGE-targeted therapy combination
RAGE therapy value
High — amplifies injury-removal response; highest reversal probability
Biomarker signal
sRAGE recovering after injury removal — favorable trajectory
Late Opportunity — Not Optimal
By F3, therapeutic leverage is greatly diminished. The AGE-RAGE loop has crossed into partial autonomy — hepatocyte mass loss has impaired sRAGE production below the neutralization threshold. Injury removal alone is no longer sufficient; fibrosis continues to progress. RAGE-targeted intervention may slow or partially arrest progression, but the probability of meaningful reversal is substantially lower than at F2. F3 is a late opportunity, not an optimal one.
Primary target
RAGE blockade to slow progression; injury removal still necessary
RAGE therapy value
Moderate — may slow progression but reversal probability substantially reduced
Biomarker signal
sRAGE declining despite injury removal — loop entering autonomy
Structural Phase — Stabilization Goals
At F4, the intervention window has closed. The fibrogenic loop is fully structural and self-sustaining — driven by the AGE-laden collagen matrix itself, independent of ongoing injury. Hepatocyte mass is critically depleted, sRAGE production is negligible, and no meaningful therapeutic leverage remains for reversal. Therapeutic goals shift entirely to stabilization and prevention of decompensation.
Primary target
Stabilization; decompensation prevention; regenerative approaches
RAGE therapy value
Low — addresses structural driver but reversal not achievable
Biomarker signal
sRAGE critically low; AGE burden dominant; loop fully autonomous
Biomarker Framework
The sRAGE Biomarker Strategy
The model generates a specific, testable biomarker prediction: the trajectory of circulating sRAGE after injury cessation is a stage-discriminating signal that identifies patients at or approaching the irreversibility threshold — and distinguishes F2 (maximum leverage) from F3 (diminished leverage) in real time.
Baseline sRAGE as Leverage Predictor
Circulating sRAGE levels at baseline correlate with viable hepatocyte mass — a proxy for remaining endogenous brake capacity. Low baseline sRAGE at F2 predicts reduced response to injury removal alone and identifies patients who need RAGE-targeted therapy to achieve reversal.
sRAGE Trajectory as Irreversibility Signal
The divergence between F2 and F3 sRAGE trajectories after injury cessation is the key biomarker signal. F2 patients show sRAGE recovery (0.68 → 0.87); F3 patients show continued decline (0.41 → 0.38). Serial sRAGE measurement at 4, 8, and 12 weeks post-injury-removal provides a real-time signal of which side of the threshold the patient is on.
sRAGE as Trial Stratification Tool
RAGE-targeted drug trials have failed in part due to patient heterogeneity — enrolling F3 patients with diminished leverage, and F4 patients where the window has closed. sRAGE-based stratification identifies the F2 population with maximum therapeutic leverage, improving trial power and reducing required sample sizes.
AGE/sRAGE Ratio as Composite Index
The ratio of circulating AGEs to sRAGE captures the balance between fibrogenic drive and endogenous brake — a single composite index of loop autonomy. The model predicts that an AGE/sRAGE ratio above a stage-specific threshold is the mechanistic definition of the irreversibility transition.
Shifting Clinical Practice
From Static Staging to Dynamic Reversibility Assessment
The framework introduces five concrete shifts in clinical practice — each grounded in the mechanistic biology of the AGE-RAGE-sRAGE axis.
Current
Static fibrosis staging (F0–F4 biopsy or FibroScan)
With this framework
Staging + reversibility assessment via model insights and sRAGE trajectory
Benefit
More accurate prognosis — tells you not just how much scar, but whether it is still actively driving disease
Current
One-size-fits-all counseling: 'it depends on the stage'
With this framework
Stage- and trajectory-specific expectations: F2 = act now, F3 = late opportunity, F4 = stabilization
Benefit
Better patient engagement and more honest, hopeful, personalized conversations
Current
Treat during active injury; limited tools for timing
With this framework
F2-prioritized intervention with quantifiable leverage; F3 as late-stage fallback
Benefit
Higher likelihood of therapeutic success; avoids treating patients outside the intervention window
Current
Limited biomarkers for regression monitoring
With this framework
sRAGE as a dynamic reversibility biomarker — serial blood test during injury removal
Benefit
Earlier detection of response or non-response; actionable signal within weeks
Current
Reactive management after decompensation
With this framework
Proactive identification of patients approaching the F2→F3 irreversibility threshold
Benefit
Opportunity for timely intervention before leverage is lost
Shared Decision-Making
Better Patient Communication
"If I stop drinking / lose weight / control my diabetes, will my liver get better?"
This model provides a more nuanced, biology-based answer than current staging alone can offer. At F2 — the point of maximum leverage — there is a strong probability of meaningful improvement with injury removal, especially combined with emerging RAGE-targeted therapies. By F3, that leverage is greatly diminished and the disease may continue progressing even with perfect adherence. This allows more honest, hopeful, and personalized conversations grounded in the patient's actual biology.
Maximum leverage. Strong likelihood of meaningful improvement with injury removal. Act now — the biology is working in your favor.
Leverage greatly diminished. Injury removal is necessary but may not be sufficient. Disease may continue progressing. Late opportunity for RAGE-targeted therapy.
Intervention window closed. Disease may continue progressing despite perfect adherence. Goals shift to stabilization and decompensation prevention.
Disease Scope
Target Disease Areas
The AGE-RAGE-sRAGE axis is active across the full spectrum of chronic liver disease etiologies. The model applies directly to each, with disease-specific parameter adjustments for AGE formation rate, injury pattern, and baseline hepatocyte mass.
Metabolic-Associated Steatotic Liver Disease
MASLD is the fastest-growing cause of cirrhosis globally, driven by the obesity and type 2 diabetes epidemics. Hyperglycemia dramatically accelerates AGE formation — MASLD patients accumulate AGE burden at 2–3× the rate of viral hepatitis patients at equivalent fibrosis stage. The model predicts that MASLD patients reach the irreversibility threshold at lower histological fibrosis scores than viral hepatitis patients, explaining the clinical observation of rapid progression in metabolically active MASH.
Key implication
Earlier intervention threshold in MASLD — F2 leverage window may be narrower and more time-sensitive than in viral hepatitis.
ALD / Alcoholic Hepatitis
Acetaldehyde, the primary metabolite of ethanol oxidation, forms protein adducts (MAA adducts) that engage RAGE with similar affinity to classical AGEs. ALD patients have both elevated RAGE ligand burden (acetaldehyde adducts + AGEs from oxidative stress) and impaired sRAGE production from alcohol-mediated hepatocyte injury. The model accommodates ALD-specific RAGE ligand kinetics and predicts accelerated loop autonomy relative to viral hepatitis.
Key implication
ALD patients may have compressed F2 intervention windows — abstinence alone insufficient at lower fibrosis stages than currently recognized.
HBV / HCV
Chronic HCV and HBV drive fibrosis through sustained inflammatory activation of HSCs, with AGE accumulation as a secondary consequence of chronic oxidative stress. Post-SVR fibrosis regression in HCV is well-documented at F1–F2 but incomplete at F3–F4 — precisely the pattern predicted by the model. The sRAGE biomarker strategy is directly applicable to post-SVR monitoring to identify patients who require additional RAGE-targeted intervention despite viral clearance.
Key implication
Post-SVR sRAGE trajectory predicts which patients will regress vs. progress despite viral clearance — identifying the subset who need additional intervention.
Drug Development Platform
Pharmaceutical Applications
The model provides a computational platform for pharmaceutical development that addresses the core failure mode of RAGE-targeted drug trials: wrong patients, wrong stage, wrong endpoint. F2-enriched trial populations with sRAGE-based stratification represent the highest-leverage path to demonstrating efficacy.
F2-Enriched Patient Stratification
Identify the F2 population with maximum therapeutic leverage using sRAGE-based biomarker criteria — improving trial power and reducing sample size requirements by targeting the stage where efficacy is most demonstrable.
Mechanism Validation
Simulate the expected sRAGE trajectory under RAGE blockade, exogenous sRAGE supplementation, or AGE-breaker treatment — generating testable predictions for Phase 2 biomarker endpoints.
Combination Therapy Design
Model the interaction between injury removal and RAGE-targeted therapy across stages — identifying synergistic combinations and optimal sequencing for the F2 leverage window.
Responder Profiling
Generate digital-twin simulations of patient subpopulations defined by baseline AGE burden, sRAGE level, and hepatocyte mass — predicting responder profiles before trial enrollment.
Partner With Us
We are actively seeking pharmaceutical partners, clinical research collaborators, and digital health organizations to validate and deploy the sRAGE biomarker strategy and the Decision Sciences simulation platform.
Discuss a Partnership